Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Diabetes

Free Subscription Articles published in Diabetes Obes Metab Retrieve available abstracts of 125 articles: HTML format Text format

Single Articles

January 2012
1. KASHYAP SR , Schauer P
   Clinical Considerations for the Management of Residual Diabetes Following Bariatric Surgery.
   Diabetes Obes Metab. 2012 Jan 30. doi: 10.1111/j.1463-1326.2012.01577.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. DUNKLEY AJ , Charles K, Gray LJ, Camosso-Stefinovic J, et al
   Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis.
   Diabetes Obes Metab. 2012 Jan 27. doi: 10.1111/j.1463-1326.2012.01571.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. LUIPPOLD G , Klein T, Mark M, Grempler R, et al
   Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
   Diabetes Obes Metab. 2012 Jan 23. doi: 10.1111/j.1463-1326.2012.01569.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. KIMURA S , Inoguchi T, Yokomizo H, Maeda Y, et al
   Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
   Diabetes Obes Metab. 2012 Jan 23. doi: 10.1111/j.1463-1326.2012.01566.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. SCHERNTHANER G , Barnett AH, Emser A, Patel S, et al
   Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
   Diabetes Obes Metab. 2012 Jan 23. doi: 10.1111/j.1463-1326.2012.01565.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. GILLEN JB , Little JP, Punthakee Z, Tarnopolsky MA, et al
   Acute high-intensity interval exercise reduces the postprandial glucose response and prevalence of hyperglycemia in patients with type 2 diabetes.
   Diabetes Obes Metab. 2012 Jan 23. doi: 10.1111/j.1463-1326.2012.01564.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. PAVLAKIS M
   The Timing of Dialysis and Kidney Transplantation in Type 1 Diabetes.
   Diabetes Obes Metab. 2012 Jan 12. doi: 10.1111/j.1463-1326.2012.01562.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. VAN DIEREN S , Czernichow S, Chalmers J, Kengne AP, et al
   Weight changes and their predictors amongst 11,140 patients with type 2 diabetes in the ADVANCE trial.
   Diabetes Obes Metab. 2012 Jan 9. doi: 10.1111/j.1463-1326.2012.01556.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. VAN DER ZIJL NJ , Moors CC, Goossens GH, Blaak EE, et al
   Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
   Diabetes Obes Metab. 2012 Jan 6. doi: 10.1111/j.1463-1326.2012.01559.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. DEVINENI D , Morrow L, Hompesch M, Skee D, et al
    Canagliflozin Improves Glycemic Control Over 28 Days in Subjects With Type 2 Diabetes Not Optimally Controlled on Insulin.
    Diabetes Obes Metab. 2012 Jan 6. doi: 10.1111/j.1463-1326.2012.01558.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. AVOGARO A
    Treating diabetes today with gliclazide MR: a matter of numbers.
    Diabetes Obes Metab. 2012;14 Suppl 1:14-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. SEINO S , Takahashi H, Takahashi T, Shibasaki T, et al
    Treating diabetes today: a matter of selectivity of sulphonylureas.
    Diabetes Obes Metab. 2012;14 Suppl 1:9-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. COLAGIURI S
    Optimal management of type 2 diabetes: the evidence.
    Diabetes Obes Metab. 2012;14 Suppl 1:3-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. HAMET P
    What matters in ADVANCE and ADVANCE-ON.
    Diabetes Obes Metab. 2012;14 Suppl 1:20-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. MATTHEWS DR
    Wisdom-based and evidence-based medicine.
    Diabetes Obes Metab. 2012;14 Suppl 1:1-2.
    PubMed     Text format     Related articles   
    
    
    
    December 2011
16. MORGAN CL , Jenkins-Jones S, Evans M, Barnett AH, et al
    Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.
    Diabetes Obes Metab. 2011 Dec 22. doi: 10.1111/j.1463-1326.2011.01552.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. YANG X , Ma RC, So WY, Kong AP, et al
    Addressing Different Biases In Analyzing Drug Use On Cancer Risk In Diabetes In Non-Clinical Trial Settings - What, Why And How?
    Diabetes Obes Metab. 2011 Dec 15. doi: 10.1111/j.1463-1326.2011.01551.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. FADINI GP , Albiero M, Menegazzo L, de Kreutzenberg SV, et al
    The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
    Diabetes Obes Metab. 2011 Dec 15. doi: 10.1111/j.1463-1326.2011.01550.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. KNOP FK , Aaboe K, Vilsboll T, Volund A, et al
    Impaired incretin effect and fasting hyperglucagonaemia characterising type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Diabetes Obes Metab. 2011 Dec 15. doi: 10.1111/j.1463-1326.2011.01549.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. GONCALVES A , Leal E, Paiva A, Teixeira Lemos E, et al
    Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
    Diabetes Obes Metab. 2011 Dec 8. doi: 10.1111/j.1463-1326.2011.01548.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. BLADBJERG E , Henriksen J, Akram S, Gram J, et al
    Effects of mealtime insulin aspart and bedtime NPH insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
    Diabetes Obes Metab. 2011 Dec 8. doi: 10.1111/j.1463-1326.2011.01547.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. KAWAMORI R , Inagaki N, Araki E, Watada H, et al
    Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Diabetes Obes Metab. 2011 Dec 6. doi: 10.1111/j.1463-1326.2011.01545.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. PONTIROLI AE , Miele L, Morabito A
    Metabolic control and risk of hypoglycemia during the first year of intensive insulin treatment in type 2 diabetes. Systematic review and meta-analysis.
    Diabetes Obes Metab. 2011 Dec 5. doi: 10.1111/j.1463-1326.2011.01543.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
24. GERRALD KR , Van Scoyoc E, Wines RC, Runge T, et al
    Saxagliptin and Sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2011 Nov 19. doi: 10.1111/j.1463-1326.2011.01540.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. SASAKI M , Imaeda K, Okayama N, Mizuno T, et al
    Effects of transglucosidase on diabetes, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2011 Nov 19. doi: 10.1111/j.1463-1326.2011.01539.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. RAFEHI H , Ververis K, Karagiannis TC
    Controversies surrounding the clinical potential of cinnamon for the management of diabetes.
    Diabetes Obes Metab. 2011 Nov 16. doi: 10.1111/j.1463-1326.2011.01538.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. GARBER AJ
    Obesity and type 2 diabetes: which patients are at risk?
    Diabetes Obes Metab. 2011 Nov 10. doi: 10.1111/j.1463-1326.2011.01536.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. FOGARI R , Zoppi A, Maffioli P, Monti C, et al
    EFFECTS OF ALISKIREN ON QT DURATION AND DISPERSION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    Diabetes Obes Metab. 2011 Nov 10. doi: 10.1111/j.1463-1326.2011.01535.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. BEST JH , Lavillotti K, Deyoung MB, Garrison LP, et al
    The effects of exenatide BID on metabolic control, medication use, and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.
    Diabetes Obes Metab. 2011 Nov 10. doi: 10.1111/j.1463-1326.2011.01533.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. WAINSTEIN J , Katz L, Engel SS, Xu L, et al
    Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Diabetes Obes Metab. 2011 Nov 7. doi: 10.1111/j.1463-1326.2011.01530.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. NARITA T , Yokoyama H, Yamashita R, Sato T, et al
    Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01526.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. ARAKI T , Hirayama M, Hiroi S, Kaku K, et al
    GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01525.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. LI Q , Chen L, Yang Z, Ye Z, et al
    Metabolic effects of bariatric surgery in type 2 diabetic patients with BMI<35 kg/m2.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01524.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. BARNETT AH
    THE ROLE OF GLP-1 MIMETICS AND BASAL INSULIN ANALOGUES IN TYPE 2 DIABETES MELLITUS: GUIDANCE FROM STUDIES OF LIRAGLUTIDE.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01523.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. WONG SK , Kong AP, So WY, Tsung BY, et al
    Use of Laparoscopic Sleeve Gastrectomy and Adjustable Gastric Banding for Suboptimally Controlled Diabetes in Hong Kong.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01528.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. RINALDI B , Di Filippo C, Capuano A, Donniacuo M, et al
    Adiponectin elevation by telmisartan ameliorates ISCHEMIC MYOCARDIUM IN Zucker Diabetic Fatty rats with metabolic syndrome.
    Diabetes Obes Metab. 2011 Nov 3. doi: 10.1111/j.1463-1326.2011.01527.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
37. BELL DS
    Beware the low urine ph - the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes.
    Diabetes Obes Metab. 2011 Oct 12. doi: 10.1111/j.1463-1326.2011.01519.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. THOMAS L , Grempler R, Eckhardt M, Himmelsbach F, et al
    Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
    Diabetes Obes Metab. 2011 Oct 10. doi: 10.1111/j.1463-1326.2011.01518.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. HEINEMANN L , Nosek L, Flacke F, Albus K, et al
    U-100, pH-Neutral Formulation of VIAject((R)) : Faster Onset of Action than Insulin Lispro in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2011 Oct 7. doi: 10.1111/j.1463-1326.2011.01516.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. D'ALESSIO D
    The role of dysregulated glucagon secretion in type 2 diabetes.
    Diabetes Obes Metab. 2011;13 Suppl 1:126-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. TUDURI E , Kieffer TJ
    Reprogramming gut and pancreas endocrine cells to treat diabetes.
    Diabetes Obes Metab. 2011;13 Suppl 1:53-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. COURTNEY M , Pfeifer A, Al-Hasani K, Gjernes E, et al
    In vivo conversion of adult alpha-cells into beta-like cells: a new research avenue in the context of type 1 diabetes.
    Diabetes Obes Metab. 2011;13 Suppl 1:47-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. AHREN B
    The future of incretin-based therapy: novel avenues--novel targets.
    Diabetes Obes Metab. 2011;13 Suppl 1:158-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. HAYASHI Y
    Metabolic impact of glucagon deficiency.
    Diabetes Obes Metab. 2011;13 Suppl 1:151-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. FARHY LS , McCall AL
    Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.
    Diabetes Obes Metab. 2011;13 Suppl 1:133-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. HARDY AB , Serino AS, Wijesekara N, Chimienti F, et al
    Regulation of glucagon secretion by zinc: lessons from the beta cell-specific Znt8 knockout mouse model.
    Diabetes Obes Metab. 2011;13 Suppl 1:112-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. WALKER JN , Ramracheya R, Zhang Q, Johnson PR, et al
    Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?
    Diabetes Obes Metab. 2011;13 Suppl 1:95-105.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. HOLST JJ , Christensen M, Lund A, de Heer J, et al
    Regulation of glucagon secretion by incretins.
    Diabetes Obes Metab. 2011;13 Suppl 1:89-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. THORENS B
    Brain glucose sensing and neural regulation of insulin and glucagon secretion.
    Diabetes Obes Metab. 2011;13 Suppl 1:82-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. CNOP M , Igoillo-Esteve M, Hughes SJ, Walker JN, et al
    Longevity of human islet alpha- and beta-cells.
    Diabetes Obes Metab. 2011;13 Suppl 1:39-46.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. GOSMAIN Y , Cheyssac C, Heddad Masson M, Dibner C, et al
    Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in alpha-cell differentiation, glucagon biosynthesis and secretion.
    Diabetes Obes Metab. 2011;13 Suppl 1:31-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. KAWAMORI D , Akiyama M, Hu J, Hambro B, et al
    Growth factor signalling in the regulation of alpha-cell fate.
    Diabetes Obes Metab. 2011;13 Suppl 1:21-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
53. ESPOSITO K , Chiodini P, Bellastella G, Maiorino MI, et al
    Proportion of patients at HbA1c target <7% with 8 classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.
    Diabetes Obes Metab. 2011 Sep 29. doi: 10.1111/j.1463-1326.2011.01512.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. RHEE NA , Vilsboll T, Knop FK
    Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.
    Diabetes Obes Metab. 2011 Sep 26. doi: 10.1111/j.1463-1326.2011.01505.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. ZHANG Q , Rajagopalan S, Marrett E, Davies MJ, et al
    Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2011 Sep 23. doi: 10.1111/j.1463-1326.2011.01498.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. RASKIN P , Heller S, Honka M, Chang PC, et al
    Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomised trial.
    Diabetes Obes Metab. 2011 Sep 23. doi: 10.1111/j.1463-1326.2011.01500.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. TAKATA H , Takeda Y, Zhu A, Cheng Y, et al
    Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
    Diabetes Obes Metab. 2011 Sep 23. doi: 10.1111/j.1463-1326.2011.01499.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. LI L , Yang M, Li Z, Yan X, et al
    Efficacy and Safety of Mitiglinide Versus Nateglinide in Newly Diagnose Patients with Type 2 Diabetes Mellitus: A Randomized Double Blind Trial.
    Diabetes Obes Metab. 2011 Sep 5. doi: 10.1111/j.1463-1326.2011.01494.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
59. ZINMAN B , Schmidt WE, Moses A, Lund N, et al
    Achieving a clinically relevant composite outcome of an HbA(1c) of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
    Diabetes Obes Metab. 2011 Aug 22. doi: 10.1111/j.1463-1326.2011.01493.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. FROHLICH E , Wahl R
    Do anti-diabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
    Diabetes Obes Metab. 2011 Aug 22. doi: 10.1111/j.1463-1326.2011.01491.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. WILLIAMS-HERMAN D , Xu L, Teng R, Golm GT, et al
    Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes.
    Diabetes Obes Metab. 2011 Aug 22. doi: 10.1111/j.1463-1326.2011.01492.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. ASCHE CV , Bode B, Busk AK, Nair S, et al
    The Economic and Clinical Benefits of Adequate Insulin Initiation and Intensification in People with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2011 Aug 11. doi: 10.1111/j.1463-1326.2011.01487.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. HENRY RR , Aroda VR, Mudaliar S, Garvey WT, et al
    Effects of Colesevelam on Glucose Absorption and Hepatic/ Peripheral Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2011 Aug 10. doi: 10.1111/j.1463-1326.2011.01486.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. STALENHOEF AF , Davidson MH, Robinson JG, Burgess T, et al
    Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Diabetes Obes Metab. 2011 Aug 6. doi: 10.1111/j.1463-1326.2011.01485.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. KOIVISTO V , Cleall S, Pontiroli AE, Giugliano D, et al
    Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Diabetes Obes Metab. 2011 Aug 5. doi: 10.1111/j.1463-1326.2011.01484.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. AHREN B , Burke B
    Using albumin to improve the therapeutic properties of diabetes treatments.
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01482.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. KOOTTE RS , Vrieze A, Holleman F, Dallinga-Thie GM, et al
    The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01483.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. BO S , Ciccone G, Rosato R, Villois P, et al
    Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients.
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01480.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. GUSTAVSON SM , Chen D, Somayaji V, Hudson K, et al
    Effects of a Long-Acting GLP-1 Mimetic (PF-04603629) on Pulse Rate and Diastolic Blood Pressure in Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01479.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. RATNER R , Wynne A, Nakhle S, Brusco O, et al
    Influence of preprandial versus postprandial insulin glulisine on weight and glycemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01478.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. GUMPRECHT J , Gosho M, Budinski D, Hounslow N, et al
    Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Diabetes Obes Metab. 2011 Aug 3. doi: 10.1111/j.1463-1326.2011.01477.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
72. FARMER AJ , Oke J, Stevens R, Holman RR, et al
    Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
    Diabetes Obes Metab. 2011 Jul 18. doi: 10.1111/j.1463-1326.2011.01475.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. DUNGAN K , Hall C, Schuster D, Osei K, et al
    Differential response between diabetes and stress induced hyperglycemia to algorithmic use of detemir and flexible mealtime aspart among stable post-cardiac surgery patients requiring intravenous insulin.
    Diabetes Obes Metab. 2011 Jul 18. doi: 10.1111/j.1463-1326.2011.01474.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. CURRIE CJ , Johnson JA
    The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.
    Diabetes Obes Metab. 2011 Jul 7. doi: 10.1111/j.1463-1326.2011.01469.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. RENSING K , Reuwer A, Arsenault B, von der Thusen J, et al
    Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
    Diabetes Obes Metab. 2011 Jul 7. doi: 10.1111/j.1463-1326.2011.01468.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. LUKASHEVICH V , Schweizer A, Shao Q, Groop PH, et al
    Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial.
    Diabetes Obes Metab. 2011 Jul 6. doi: 10.1111/j.1463-1326.2011.01467.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. BOSI E , Ellis GC, Wilson CA, Fleck PR, et al
    Alogliptin as a Third Oral Antidiabetic Drug in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Metformin and Pioglitazone: A 52-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
    Diabetes Obes Metab. 2011 Jul 6. doi: 10.1111/j.1463-1326.2011.01463.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
78. DOBBINS RL , O'Connor-Semmes R, Kapur A, Kapitza C, et al
    Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2 (SGLT2) Reduces Serum Glucose in Type 2 Diabetes Mellitus Patients.
    Diabetes Obes Metab. 2011 Jul 6. doi: 10.1111/j.1463-1326.2011.01462.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
79. BORGES JL , Bilezikian JP, Jones-Leone AR, Acusta AP, et al
    A Randomized, Parallel Group, Double-blind, Multicentre Study Comparing the Efficacy and Safety of Avandamet (Rosiglitazone/Metformin) and Metformin on Long-term Glycaemic Control and Bone Mineral Density after 80 Weeks of Treatment in Drug-naive Type
    Diabetes Obes Metab. 2011 Jun 17. doi: 10.1111/j.1463-1326.2011.01461.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. KAKU K , Itayasu T, Hiroi S, Hirayama M, et al
    Efficacy and Safety of Alogliptin added to Pioglitazone in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Long-Term Extension Study.
    Diabetes Obes Metab. 2011 Jun 17. doi: 10.1111/j.1463-1326.2011.01460.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. OWENS DR , Luzio SD, Sert-Langeron C, Riddle MC, et al
    EFFECTS OF INITIATION AND TITRATION OF A SINGLE PRE-PRANDIAL DOSE OF INSULIN GLULISINE WHILE CONTINUING TITRATED INSULIN GLARGINE IN TYPE 2 DIABETES: A 6-MONTH 'PROOF-OF-CONCEPT' STUDY.
    Diabetes Obes Metab. 2011 Jun 16. doi: 10.1111/j.1463-1326.2011.01459.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. STROJEK K , Yoon K, Hruba V, Elze M, et al
    Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2011 Jun 15. doi: 10.1111/j.1463-1326.2011.01434.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. WANG Y , Li L, Yang M, Liu H, et al
    Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Diabetes Obes Metab. 2011 Jun 8. doi: 10.1111/j.1463-1326.2011.01436.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. PONTIROLI AE , Miele L, Morabito A
    Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes. Systematic review and meta-analysis.
    Diabetes Obes Metab. 2011 Jun 3. doi: 10.1111/j.1463-1326.2011.01433.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. JOLIVALT CG , Fineman M, Deacon CF, Carr RD, et al
    GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.
    Diabetes Obes Metab. 2011 Jun 2. doi: 10.1111/j.1463-1326.2011.01431.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
86. PESKIN BR , Shcheprov AV, Boye KS, Bruce S, et al
    Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist versus traditional therapies for type 2 diabetes: A simulation analysis.
    Diabetes Obes Metab. 2011 May 30. doi: 10.1111/j.1463-1326.2011.01430.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. FERNANDEZ M , Gastaldelli A, Triplitt C, Hardies J, et al
    Metabolic Effects of Muraglitazar in Type 2 Diabetic Subjects.
    Diabetes Obes Metab. 2011 May 26. doi: 10.1111/j.1463-1326.2011.01429.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. BAGGER JI , Knop FK, Holst JJ, Vilsboll T, et al
    Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Diabetes Obes Metab. 2011 May 26. doi: 10.1111/j.1463-1326.2011.01427.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. HUSSEY SE , McGee SL, Garnham A, Wentworth JM, et al
    Exercise training increases adipose tissue GLUT4 expression in patients with type 2 diabetes.
    Diabetes Obes Metab. 2011 May 25. doi: 10.1111/j.1463-1326.2011.01426.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. CHAUDHURI A , Dandona P
    Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes.
    Diabetes Obes Metab. 2011 May 13. doi: 10.1111/j.1463-1326.2011.01423.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. HENRY RR , Smith SR, Schwartz SL, Mudaliar SR, et al
    Effects of Saxagliptin on beta-Cell Stimulation and Insulin Secretion in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2011 May 6. doi: 10.1111/j.1463-1326.2011.01417.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. PORTA M , Maldari P, Mazzaglia F
    NEW APPROACHES TO THE TREATMENT OF DIABETIC RETINOPATHY.
    Diabetes Obes Metab. 2011 May 2. doi: 10.1111/j.1463-1326.2011.01415.
    PubMed     Text format     Related articles   
    
    
    
    
93. CZUPRYNIAK L , Szymanska-Garbacz E, Pawlowski M, Saryusz-Wolska M, et al
    In support of an early intensive treatment of type 2 diabetes and not necessarily of early polypharmacy.
    Diabetes Obes Metab. 2011;13:474-5.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
94. KONG AP , Yamasaki A, Ozaki R, Saito H, et al
    A randomized controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Diabetes Obes Metab. 2011 Apr 14. doi: 10.1111/j.1463-1326.2011.01411.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. WATSON L , Wilson BP, Alsop J, Kumar S, et al
    Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?
    Diabetes Obes Metab. 2011 Apr 11. doi: 10.1111/j.1463-1326.2011.01413.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. SAWAKHANDA RB , Dharmalingam M, Kumar S, Bell D, et al
    Triple oral fixed dose diabetes polypill vs. Insulin plus Metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Diabetes Obes Metab. 2011 Apr 7. doi: 10.1111/j.1463-1326.2011.01408.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. FU AZ , Qiu Y, Davies MJ, Radican L, et al
    Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
    Diabetes Obes Metab. 2011 Apr 1. doi: 10.1111/j.1463-1326.2011.01405.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
98. KUMAR A , Negi G, Sharma SS
    JSH-23 targets nuclear factor kappa B (NF-kappaB) and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence.
    Diabetes Obes Metab. 2011 Mar 29. doi: 10.1111/j.1463-1326.2011.01402.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. MORGADO C , Pereira-Terra P, Tavares I
    Alpha-lipoic acid normalizes nociceptive neuronal activity at the spinal cord of diabetic rats.
    Diabetes Obes Metab. 2011 Mar 17. doi: 10.1111/j.1463-1326.2011.01399.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. FADINI GP , de Kreutzenberg SV, Mariano V, Boscaro E, et al
     Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized cross-over trial comparing detemir versus glargine.
     Diabetes Obes Metab. 2011 Mar 16. doi: 10.1111/j.1463-1326.2011.01396.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. EVANS M , Schumm-Draeger PM, Vora J, King AB, et al
     A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.
     Diabetes Obes Metab. 2011 Mar 16. doi: 10.1111/j.1463-1326.2011.01395.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. RHOADS GG , Dain MP, Zhang Q, Kennedy L, et al
     Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine vs. NPH insulin in type 2 diabetes.
     Diabetes Obes Metab. 2011 Mar 16. doi: 10.1111/j.1463-1326.2011.01394.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. THONG KY , Jose B, Sukumar N, Cull ML, et al
     Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
     Diabetes Obes Metab. 2011 Mar 16. doi: 10.1111/j.1463-1326.2011.01393.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. GOMIS R , Espadero RM, Jones R, Woerle HJ, et al
     Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study.
     Diabetes Obes Metab. 2011 Mar 15. doi: 10.1111/j.1463-1326.2011.01391.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. REASNER C , Olansky L, Seck TL, Williams-Herman DE, et al
     The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2011 Mar 15. doi: 10.1111/j.1463-1326.2011.01390.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
106. TOREKOV SS , Kipnes MS, Harley RE, Holst JJ, et al
     Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.
     Diabetes Obes Metab. 2011 Mar 1. doi: 10.1111/j.1463-1326.2011.01388.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. HATA T , Mera Y, Kawai T, Ishii Y, et al
     JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats.
     Diabetes Obes Metab. 2011 Mar 1. doi: 10.1111/j.1463-1326.2011.01387.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     February 2011
108. FORST T , Uhlig-Laske B, Ring A, Ritzhaupt A, et al
     The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2011 Feb 25. doi: 10.1111/j.1463-1326.2011.01386.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
109. RABBANI N , Thornalley PJ
     Emerging role of thiamine therapy for prevention and treatment of early stage diabetic nephropathy.
     Diabetes Obes Metab. 2011 Feb 22. doi: 10.1111/j.1463-1326.2011.01384.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
110. LEITER LA , Betteridge DJ, Farnier M, Guyton JR, et al
     Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin versus statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
     Diabetes Obes Metab. 2011 Feb 18. doi: 10.1111/j.1463-1326.2011.01383.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
111. NOWICKI M , Rychlik I, Haller H, Warren ML, et al
     Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
     Diabetes Obes Metab. 2011 Feb 17. doi: 10.1111/j.1463-1326.2011.01382.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
112. ESPOSITO K , Cozzolino D, Bellastella G, Maiorino MI, et al
     Dipeptydil peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2011 Feb 14. doi: 10.1111/j.1463-1326.2011.01380.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
113. GOYAL S , Bharti S, Bhatia J, Nag TC, et al
     Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischemic reperfusion injury in experimental diabetes.
     Diabetes Obes Metab. 2011 Feb 14. doi: 10.1111/j.1463-1326.2011.01377.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     January 2011
114. FEIG PU , Shah S, Hermanowski Vosatka A, Plotkin D, et al
     Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.
     Diabetes Obes Metab. 2011 Jan 28. doi: 10.1111/j.1463-1326.2011.01375.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
115. KAMPMANN U , Hoeyem P, Mengel A, Schmitz O, et al
     Insulin dose response studies in severely insulin resistant type 2 diabetes - evidence for effectiveness of very high insulin doses.
     Diabetes Obes Metab. 2011 Jan 27. doi: 10.1111/j.1463-1326.2011.01373.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
116. SHAH PK , Mudaliar S, Chang AR, Aroda V, et al
     Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
     Diabetes Obes Metab. 2011 Jan 27. doi: 10.1111/j.1463-1326.2011.01370.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
117. ROE ND , Thomas DP, Ren J
     Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction.
     Diabetes Obes Metab. 2011 Jan 27. doi: 10.1111/j.1463-1326.2011.01369.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
118. ESPOSITO K , Maiorino MI, Di Palo C, Gicchino M, et al
     Effects of pioglitazone vs metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized controlled trial.
     Diabetes Obes Metab. 2011 Jan 21. doi: 10.1111/j.1463-1326.2011.01367.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
119. UMPIERREZ GE , Blevins T, Rosenstock J, Cheng C, et al
     The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
     Diabetes Obes Metab. 2011 Jan 19. doi: 10.1111/j.1463-1326.2011.01366.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
120. BARRINGTON P , Chien JY, Showalter HD, Schneck K, et al
     A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analog, in patients with type 2 diabetes.
     Diabetes Obes Metab. 2011 Jan 19. doi: 10.1111/j.1463-1326.2011.01364.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
121. TREMBLAY AJ , Lamarche B, Deacon CF, Weisnagel SJ, et al
     Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
     Diabetes Obes Metab. 2011 Jan 12. doi: 10.1111/j.1463-1326.2011.01362.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
122. SEEGER JP , Thijssen DH, Noordam K, Cranen ME, et al
     Exercise training improves physical fitness and vascular function in children with type 1 diabetes.
     Diabetes Obes Metab. 2011 Jan 12. doi: 10.1111/j.1463-1326.2011.01361.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
123. KASICHAYANULA S , Chang M, Hasegawa M, Liu X, et al
     Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of SGLT2, in Japanese subjects without and with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2011 Jan 12. doi: 10.1111/j.1463-1326.2011.01359.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
124. ALAM ML , Van der Schueren BJ, Ahren B, Wang GC, et al
     Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase 4 activity in obese patients with type 2 diabetes.
     Diabetes Obes Metab. 2011 Jan 6. doi: 10.1111/j.1463-1326.2011.01358.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     October 2010
125. 
     Abstracts of the 1st International Diabetes and Obesity Forum (IDOF). October 21-23, 2010. Athens, Greece.
     Diabetes Obes Metab. 2010;12 Suppl 1:1-96.
     PubMed     Text format     Related articles   
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: